Browse the evidence

Glucose metrics continued to decline after week 1 in high-carbohydrate diets.

High-carbohydrate diets may lead to improved glucose metrics over time.

The number of participants with abnormal glucose tolerance decreased in high-carbohydrate groups.

Transitioning to a high-carbohydrate diet may improve glucose tolerance in individuals.

DNL fatty acid levels decrease on a low-carbohydrate (LC) diet and do not change on a low-fat (LF) diet.

Low-carbohydrate diets may be beneficial for reducing certain fatty acids associated with insulin resistance.

Changes in dietary carbohydrate intake correlate with changes in DNL fatty acid levels (16:1n7 directly and 18:2n6 indirectly).

Monitoring carbohydrate intake may help in managing fatty acid levels related to insulin resistance.

Glucose metrics continued to decline after week 1 in high-carbohydrate diets.

Monitoring glucose metrics can provide insights into the effectiveness of dietary changes.

The number of participants with abnormal glucose tolerance decreased in high-carbohydrate groups.

High-carbohydrate diets may improve glucose tolerance in individuals transitioning from low-carbohydrate diets.

Parameters of glucose metabolism improved as a result of the course.

Improving glucose metabolism can be a beneficial outcome of weight loss programs.

Parameters of glucose metabolism improved along with psychological indicators of eating impulses.

Improving glucose metabolism and psychological factors can enhance weight loss strategies.

Both 0839 and 0833 improved metabolic parameters and reduced body weight primarily by fat mass reduction.

These compounds may be effective for fat loss and improving metabolic health.

Optimal obesity management requires a systematic assessment that extends beyond body mass index (BMI).

Clinicians should incorporate comprehensive assessments in obesity management.

Obesity is a significant pathogenic factor for multiple chronic conditions and ranks as the sixth leading risk factor for mortality and disability nationwide.

Healthcare practitioners should recognize obesity as a critical factor in managing chronic diseases.

Dual agonists represent a transformative therapeutic class for metabolic disease management.

Clinicians should consider dual agonists as a key component in the management of metabolic diseases.

RYGB showed significantly greater weight loss than SG at both 12 months (30.3% vs. 25.4%; p < 0.001) and 24 months (26.3% vs. 21.4%; p < 0.001).

Practitioners should consider RYGB for patients seeking greater weight loss outcomes.

Metabolic bariatric surgery is associated with improvements in weight, AHI, upper airway collapsibility, and loop gain.

Practitioners may consider metabolic bariatric surgery as a treatment option for patients with OSA to improve various physiological traits.

Key secondary endpoints include categorical weight-loss thresholds, changes in anthropometric and cardiometabolic measures, and comprehensive safety and tolerability assessments.

The trial will assess various health metrics alongside weight loss to evaluate overall impact.

Obesity without metabolic abnormalities increases the risk of atherosclerotic cardiovascular disease (ASCVD) by 46% in men and 34% in women compared to those with normal BMI.

Practitioners should recognize that obesity, even without metabolic abnormalities, poses significant cardiovascular risks.

Obesity is associated with increased risk of heart failure (HF), with a 63% increase in men and a 69% increase in women compared to those with normal BMI.

Practitioners should be aware of the significant risk of heart failure in obese patients, regardless of metabolic health.

Relative preservation of fat-free mass, muscle strength, and resting metabolic rate was observed in one dietary context.

Choosing the right dietary context may help preserve muscle and metabolic health during weight loss.

Discontinuation of GLP-1 receptor agonists is associated with substantial weight regain of 60%-90% within one year.

Clinicians should anticipate significant weight regain in patients discontinuing GLP-1RA therapy.

Placebo-adjusted weight loss was significantly lower in T2D versus obesity trials (pooled ratio: 0.61, 95% C.I. 0.56; 0.67).

Clinicians should consider that patients with T2D may experience less weight loss from incretin therapies compared to those with obesity alone.

Study-level diabetes status, age, BMI, sex distribution, ethnicity, and cardiometabolic comorbidities significantly correlated with BW loss at univariate analysis.

Understanding these correlates can help tailor weight loss strategies in clinical practice.

GLP-1RA therapy was associated with significant weight, glycemic, and renal benefits that were attenuated in Black adults.

It is important for practitioners to recognize that GLP-1RA therapy may have varying effectiveness across different racial groups.

Incretin-based therapies such as GLP-1 RA improve symptoms, exercise capacity, congestion, and reduce heart failure events in obesity-related HFpEF.

Practitioners may consider incretin-based therapies as a treatment option for improving outcomes in patients with obesity-related HFpEF.

Incretin-based therapies lead to reduced ectopic fat depositions in multiple organs and favourable cardiac remodelling.

Incretin-based therapies may be effective in reducing harmful fat deposits and improving heart structure in affected patients.